184 related articles for article (PubMed ID: 31726199)
1. Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment.
Jana A; Narula P; Chugh A; Kulshreshtha R
Int J Pharm; 2019 Dec; 572():118789. PubMed ID: 31726199
[TBL] [Abstract][Full Text] [Related]
2. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
3. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
[TBL] [Abstract][Full Text] [Related]
4. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G
Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
7. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
8. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
9. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Li Y; Liu Y; Ren J; Deng S; Yi G; Guo M; Shu S; Zhao L; Peng Y; Qi S
J Neurooncol; 2018 Jul; 138(3):499-508. PubMed ID: 29876787
[TBL] [Abstract][Full Text] [Related]
10. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
11. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
12. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.
Lee TJ; Yoo JY; Shu D; Li H; Zhang J; Yu JG; Jaime-Ramirez AC; Acunzo M; Romano G; Cui R; Sun HL; Luo Z; Old M; Kaur B; Guo P; Croce CM
Mol Ther; 2017 Jul; 25(7):1544-1555. PubMed ID: 28109960
[TBL] [Abstract][Full Text] [Related]
13. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
[TBL] [Abstract][Full Text] [Related]
14. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM
Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Proteomic Profiling of Tachyplesin I Targets in U251 Gliomaspheres.
Li X; Dai J; Tang Y; Li L; Jin G
Mar Drugs; 2017 Jan; 15(1):. PubMed ID: 28106765
[TBL] [Abstract][Full Text] [Related]
16. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Shi L; Chen J; Yang J; Pan T; Zhang S; Wang Z
Brain Res; 2010 Sep; 1352():255-64. PubMed ID: 20633539
[TBL] [Abstract][Full Text] [Related]
17. Mir-758-5p Suppresses Glioblastoma Proliferation, Migration and Invasion by Targeting ZBTB20.
Liu J; Jiang J; Hui X; Wang W; Fang D; Ding L
Cell Physiol Biochem; 2018; 48(5):2074-2083. PubMed ID: 30099442
[TBL] [Abstract][Full Text] [Related]
18. Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy.
Shatsberg Z; Zhang X; Ofek P; Malhotra S; Krivitsky A; Scomparin A; Tiram G; Calderón M; Haag R; Satchi-Fainaro R
J Control Release; 2016 Oct; 239():159-68. PubMed ID: 27569663
[TBL] [Abstract][Full Text] [Related]
19. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
20. C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.
Thanasupawat T; Glogowska A; Burg M; Krcek J; Beiko J; Pitz M; Zhang GJ; Hombach-Klonisch S; Klonisch T
Mol Oncol; 2018 Sep; 12(9):1464-1479. PubMed ID: 29949238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
